跳至主要内容
临床试验/NCT00654680
NCT00654680已完成3 期

A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Subjects With ED Solely Secondary to Traumatic Spinal Cord Injury

Bayer0 个研究点目标入组 418 人开始时间: 2002年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Bayer
入组人数
418
主要终点
International Index of Erectile Function-Erectile Function domain

研究概览

简要总结

Investigate efficacy and safety of Vardenafil in patients with spinal cord injury

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Males ≥18 years with erectile dysfunction (ED) solely as a result of traumatic spinal cord injury (SCI) for ≥6 months with demonstrated 50% failure in intercourse attempts during the 4-week run-in period.
  • Stable heterosexual relationship for at least 1 month.

排除标准

  • Subjects with unstable medical or psychiatric conditions or using prohibited concomitant medications
  • Primary hypoactive sexual desire
  • History of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month
  • Nitrate therapy
  • Other exclusion criteria apply according to US Product Information or Summary of Product Characteristics

研究组 & 干预措施

Arm 1

Experimental

干预措施: Vardenafil (Levitra, BAY38-9456) (Drug)

Arm 2

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

International Index of Erectile Function-Erectile Function domain

时间窗: 12 weeks

次要结局

  • Other diary based variables(12 weeks)
  • Sexual Encounter Profile Question 2(12 weeks)
  • Sexual Encounter Profile Question 3(12 weeks)
  • Safety and tolerability(12 weeks)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验